NCT04783636 is a Phase 1 clinical trial of leuprorelin acetate 3.75mg in Prostate Cancer, sponsored by Peptron, Inc..

Who is sponsoring NCT04783636?

NCT04783636 is sponsored by Peptron, Inc..

What drugs are being tested in NCT04783636?

Interventions in NCT04783636: leuprorelin acetate 3.75mg.

What condition does NCT04783636 study?

NCT04783636 studies Prostate Cancer.

Is NCT04783636 still recruiting?

NCT04783636 is currently status unknown. Last updated 17 March 2021.

Last reviewed 2021-03-17 · How we verify

NCT04783636

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

To Compare the Safety and Pharmacokinetics of PT105 With PT105R in Healthy Postmenopausal Female Volunteers

Status unknown Phase 1 Last updated 17 March 2021

What this trial tests

Phase 1 trial testing leuprorelin acetate 3.75mg in Prostate Cancer in 40 participants. Status unknown.

Timeline

11 March 2021

Primary endpoint
20 July 2021

20 July 2021

Quick facts

Lead sponsor	Peptron, Inc.
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	40
Start date	11 March 2021
Primary completion	20 July 2021
Estimated completion	20 July 2021

Drugs / interventions tested

leuprorelin acetate 3.75mg — full drug profile →

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Peptron, Inc. — full company profile →

Who can join

19 and older, female only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of study is to compare the safety and pharmacokinetics of PT105 with PT105R in healthy postmenopausal female volunteers

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Peptron, Inc. trials

Trials by the same sponsor.

NCT04269642 — SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04783636 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peptron, Inc.
Last refreshed: 17 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04783636.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing